Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;4(5):295-302.
doi: 10.1016/j.jpha.2014.02.002. Epub 2014 Mar 13.

Pioglitazone: A review of analytical methods

N Satheeshkumar  1 , S Shantikumar  1 , R Srinivas  2
Affiliations
Review

Pioglitazone: A review of analytical methods

N Satheeshkumar et al. J Pharm Anal. 2014 Oct.

Abstract

Pioglitazone is an oral anti-hyperglycemic agent. It is used for the treatment of diabetes mellitus type 2. It selectively stimulates nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-gamma). It was the tenth-best-selling drug in the U.S. in 2008. This article examines published analytical methods reported so far in the literature for the determination of pioglitazone in biological samples and pharmaceutical formulations. They include various techniques like electrochemical methods, spectrophotometry, capillary electrophoresis, high-performance liquid chromatography, liquid chromatography-electrospray ionization-tandem mass spectrometry and high-performance thin layer chromatography.

Keywords: Analytical methods; Diabetes mellitus type 2; Pioglitazone.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structure of pioglitazone.
Fig. 2
Fig. 2
Overview of analytical methods for estimation of pioglitazone in biological and pharmaceutical samples.
Fig. 3
Fig. 3
Solubility chart of pioglitazone (generated using JMP software).
Fig. 4
Fig. 4
Various diluents used for the analysis of pioglitazone.
Fig. 5
Fig. 5
Sensitive and greener HPLC methods among the reported.
Fig. 6
Fig. 6
Comparison of sensitivities of various techniques for estimation of pioglitazone.
See this image and copyright information in PMC

References

    1. Belcher G., Lambert C., Edwards G. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract. 2005;70:53–62. - PubMed
    1. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest. 2000;106:467–472. - PMC - PubMed
    1. Miyazaki Y., Glass L., Triplitt C. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia. 2001;44:2210–2219. - PubMed
    1. Miyazaki Y., Mahankali A., Matsuda M. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710–719. - PubMed
    1. Iacobellis G. Nova Science Publishers; New York: 2006. Drug–Drug Interactions in the Metabolic Syndrome.

LinkOut - more resources